Real-Time PCR, Digital PCR and End-Point PCR Market Report 2026

The real-time pcr, digital pcr and end-point pcr market size has grown strongly in recent years. It will grow from $41.55 billion in 2025 to $45.46 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to expansion of molecular diagnostics applications, rising prevalence of infectious diseases, increased use of pcr in clinical research, growth of genetic testing laboratories, availability of advanced pcr instruments.

The real-time pcr, digital pcr and end-point pcr market size is expected to see rapid growth in the next few years. It will grow to $67.76 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing adoption of personalized medicine diagnostics, rising investments in genomics research, expansion of point-of-care molecular testing, growing demand for ultra-sensitive detection methods, increased automation in molecular laboratories. Major trends in the forecast period include increasing adoption of digital pcr for precision quantification, rising demand for high-throughput pcr systems, growing use of multiplex pcr assays, expansion of automated pcr workflows, enhanced focus on data accuracy and sensitivity.

The rising incidence of infectious diseases is expected to drive the growth of the real-time PCR, digital PCR, and end-point PCR markets in the coming years. Infectious diseases are illnesses caused by the invasion and proliferation of pathogenic microorganisms, including bacteria, viruses, fungi, and parasites. Real-time PCR, digital PCR, and end-point PCR are widely used in infectious disease management to detect and quantify specific pathogens or their genetic material, track disease progression, and enable rapid diagnosis of infections such as HIV, hepatitis, respiratory viral infections, and tuberculosis. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, reflecting an increase of 1,295 cases. Therefore, the growing incidence of infectious diseases is driving the growth of the real-time PCR, digital PCR, and end-point PCR market.

Major companies operating in the real-time PCR, digital PCR, and end-point PCR markets are concentrating on the development of next-generation platforms to improve assay sensitivity, enhance precision, and strengthen overall clinical performance. These innovations are intended to support highly accurate detection of low-abundance nucleic acids, rare genetic mutations, and copy number variations, benefiting both research and clinical diagnostic applications. Digital PCR, in particular, enables absolute quantification, making it especially valuable for applications that demand high sensitivity and reproducibility. For instance, in September 2024, QIAGEN N.V., a Germany-based provider of sample and assay technologies for molecular diagnostics, launched the QIAcuityDx Digital PCR System for clinical oncology diagnostics, along with more than 100 newly validated assays available through its GeneGlobe platform. The system combines sample partitioning, thermocycling, and imaging into a single automated workflow, simplifying operations in clinical and research laboratories. Designed to support applications such as non-invasive liquid biopsy testing, the QIAcuityDx platform highlights QIAGEN’s focus on advancing diagnostic precision and improving clinical outcomes.

In April 2024, Bio-Rad Laboratories Inc., a US-based research company specializing in real-time PCR and digital PCR technologies, partnered with Oncocyte Corporation. Through this collaboration, the companies aim to develop and commercialize advanced transplant monitoring solutions using droplet digital PCR technology, enabling non-invasive evaluation of organ health through sensitive analysis of cell-free DNA biomarkers to improve patient outcomes in transplant care. Oncocyte Corporation is a US-based biotechnology research company focused on precision diagnostics for cancer and transplant monitoring.

Major companies operating in the real-time pcr, digital pcr and end-point pcr market are F. Hoffmann La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Co., Agilent Technologies Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., QIAGEN N.V., Eppendorf Group, Promega Corporation, Meridian Bioscience Inc., Takara Bio Inc., Cole-Parmer Instrument Company LLC, Bioneer Corporation, Enzo Life Sciences Inc., Analytik Jena AG, Fluidigm Corporation, Elitech Group SAS, Microsynth AG, Stilla Technologies SAS, HTG Molecular Diagnostics Inc., AITbiotech Pte Ltd., Bio Molecular Systems, JN Medsys Pte Ltd., Biomeme Inc.

North America was the largest region in the real-time PCR, digital PCR, and end-point PCR market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the real-time pcr, digital pcr and end-point pcr market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the real-time pcr, digital pcr and end-point pcr market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the real-time, digital, and end-point PCR market by increasing costs of imported thermal cyclers, optical components, reagents, enzymes, and precision plastics used in PCR consumables. Diagnostic laboratories and research institutions in North America and Europe are most affected due to reliance on imported instruments, while Asia-Pacific faces higher manufacturing and export costs. These tariffs are raising assay prices and slowing laboratory expansion plans. However, they are also encouraging local reagent manufacturing, regional instrument assembly, and innovation in cost-efficient PCR platforms, strengthening supply chain stability.

The real-time pcr, digital pcr and end-point pcr market research report is one of a series of new reports that provides real-time pcr, digital pcr and end-point pcr market statistics, including real-time pcr, digital pcr and end-point pcr industry global market size, regional shares, competitors with a real-time pcr, digital pcr and end-point pcr market share, detailed real-time pcr, digital pcr and end-point pcr market segments, market trends and opportunities, and any further data you may need to thrive in the real-time pcr, digital pcr and end-point pcr industry. This real-time pcr, digital pcr and end-point pcr market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Real-time PCR, digital PCR, and end-point PCR are molecular biology and genetic analysis techniques used to amplify and analyze DNA samples. Real-time polymerase chain reaction is a laboratory method that enables the amplification and quantification of DNA or RNA molecules. Digital PCR is considered a third-generation PCR technology that allows highly accurate quantification by partitioning a sample into numerous isolated compartments. End-point PCR, also known as conventional PCR, is a basic molecular biology technique used to amplify a specific DNA sequence from a sample. These PCR methods are widely applied in clinical applications such as bacterial detection, DNA fingerprinting, and the diagnosis of genetic disorders.

The primary products associated with real-time PCR, digital PCR, and end-point PCR include instruments, consumables and reagents, software, and services. Instruments are devices or equipment designed for functions such as measurement, analysis, manipulation, or control of physical, chemical, or biological processes. Technologies including quantitative PCR, end-point PCR, and digital PCR are used across clinical, research, forensic, and other applications by various end users, including hospitals, diagnostic laboratories, pharmaceutical companies, biotechnology firms, and contract research organizations.

The real-time PCR, digital PCR, and end-point PCR market include revenues earned by entities by providing services such as quantitative analysis, real-time monitoring, high sensitivity and specificity, gene expression analysis, absolute quantification, rare event detection, qualitative detection, and molecular cloning. The market value includes the value of related goods sold by the service provider or included within the service offering. The real-time PCR, digital PCR, and end-point PCR market also include sales of thermal cyclers, fluorescent probes, quantitative data output, standard curves, real-time PCR reagents, partitioning chips or plates, digital PCR instruments, and PCR master mixes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.